BioSpace News Archive

Biotech Beach

ChromaDex to Present at Benzinga’s Global Small Cap Conference on May 13, 2021

ChromaDex Corp. is scheduled to participate in a virtual presentation at the Benzinga Small Cap Conference on Thursday, May 13, 2021 at 11:30am ET.

May 3, 2021
·
3 min read
Deals

Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest

Aceragen, Inc. announced the acquisition of Enzyvant’s RVT-801, an investigational enzyme replacement therapy for acid ceramidase deficiency presenting as Farber disease, a lysosomal storage disease with a unique, severe inflammatory phenotype for which no disease-specific therapy exists.

May 3, 2021
·
7 min read
Mallinckrodt Presents Data Evaluating Acthar® Gel (Repository Corticotropin Injection) for the Treatment of Severe Keratitis at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Phase 4 open-label study showed clinically important improvement in the patient-reported Impact of Dry Eye on Everyday Life (IDEEL) symptom bother score, the study’s primary outcome measure

May 3, 2021
·
11 min read
Pharm Country

Merck Hosts Organon Investor Day Outlining New Company’s Vision, Focus and Business Model for Sustained Growth

Merck, known as MSD outside the United States and Canada, will host Organon management at a meeting with the investment community.

May 3, 2021
·
10 min read
Business

Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors

Eagle Pharmaceuticals, Inc. announced the appointment of Luciana Borio, MD, to its Board of Directors.

May 3, 2021
·
6 min read
BioMidwest

Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day

Company continues to focus on expanding its reach and organic growth, expense control, and laying foundation for advancing leadership position in genetic testing and precision medicine

May 3, 2021
·
8 min read
Business

Cabaletta Bio Reports First Quarter 2021 Financial Results and Provides New Pipeline Updates

Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021

May 3, 2021
·
10 min read
BioMidwest

Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to sell select operating assets and intellectual property, including the Vectra® test, from Myriad Autoimmune’s business unit to Labcorp for $150 million in cash.

May 3, 2021
·
6 min read
Policy

Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease

Amicus Therapeutics announced the completion of a successful Type B Pre-Biologics License Application meeting with the U.S. Food and Drug Administration for AT-GAA, its investigational two-component therapy for the treatment of Pompe disease.

May 3, 2021
·
5 min read
Policy

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine TumorsFirst NDA submission by HUTCHMED in the U.S.; product launch preparations underway

HUTCHMED Limited announces that it completed the rolling submission of a New Drug Application to the U.S. Food and Drug Administration for surufatinib for the treatment of pancreatic and extra-pancreatic neuroendocrine tumors.

May 3, 2021
·
9 min read